PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2022
CASE
AUTH/3601/1/22 Boehringer Ingelheim

Boehringer Ingelheim: β€˜Unique convenience’ claim in Trajenta digital banner (AUTH/3601/1/22)

Complaint about use of β€˜unique’ in a Trajenta (linagliptin) HCP digital banner claim. Panel ruled no breach of Clause 14.4, accepting the…

2022
CASE
AUTH/3632/4/22 Daiichi-Sankyo UK

AUTH/3632/4/22: Daiichi Sankyo – Lixiana (edoxaban) initiation video on learned society site (No breach)

Complaint alleged a Lixiana initiation β€œwebinar” omitted hepatic monitoring/contraindications and included a dosing interaction error. Panel found no breach as content was…

2022
CASE
AUTH/3635/4/22 Novartis Pharmaceuticals UK ⭐ Case of the Week

Novartis Entresto podcast: unsubstantiated β€˜energy’ claim, β€˜best’ implied superiority, and renal safety downplayed (AUTH/3635/4/22)

PMCPA found Novartis breached the ABPI Code over an Entresto nurse podcast: an unsubstantiated β€˜energy’ claim, β€˜best’ implying superiority, and unqualified renal…

2022
CASE
AUTH/3669/6/22 Small Pharma

Small Pharma website: pipeline content and unclear audience separation led to high standards breach (AUTH/3669/6/22)

Small Pharma’s open-access website discussed psychedelic pipeline programmes using strong, unqualified language without clearly identifying the intended audience. PMCPA ruled a breach…

2022
CASE
AUTH/3696/10/22 SOBI

AUTH/3696/10/22: Complainant v SOBI β€” Guardian sponsored corporate article (No breach)

Anonymous complaint alleged a Guardian-sponsored SOBI corporate article was disguised promotion and misleading. PMCPA Panel ruled no breach of Clauses 3.6, 5.1,…

2021
CASE
Novartis Pharmaceuticals UK

Novartis breached ABPI Code over Jakavi webpage claim implying statistically significant survival benefit vs BAT

PMCPA found Novartis’ Jakavi HCP webpage claim β€œImproved survival benefit compared with BAT” misleading and unsubstantiated because it implied statistically significant survival…

2022
CASE
AUTH/3705/11/22 AbbVie

AbbVie: Rinvoq website dosing statement β€˜with or without food’ (AUTH/3705/11/22) – no breach

Complaint alleged Rinvoq dosing web copy implied it could be taken with any food (incl. grapefruit) despite SPC advice to avoid grapefruit.…

2022
CASE
AUTH/3699/10/22 GlaxoSmithKline ⭐ Case of the Week

AstraZeneca v GSK: Trelegy COPD NMA headline claim ruled misleading (AUTH/3699/10/22)

GSK’s HCP webpage/video used an NMA to headline β€œgreater exacerbation reduction” vs other COPD SITTs. PMCPA ruled the headline comparison misleading (Clauses…

2023
CASE
AUTH/3735/2/23 Eli Lilly

AUTH/3735/2/23: Health professional complaint about Lilly representative visits to dermatology department (No breach)

A health professional alleged a Lilly representative repeatedly visited a dermatology department without prior authorisation and dropped off items/samples. The Panel found…

2023
CASE
AUTH/3793/7/23 Daiichi-Sankyo UK

Daiichi Sankyo: sponsorship disclosure buried at bottom of charity website articles (AUTH/3793/7/23)

Two sponsored cardiovascular disease articles on a charity website disclosed Daiichi Sankyo’s involvement only at the bottom of long pages. PMCPA found…

2021
CASE
GrΓΌnenthal

GrΓΌnenthal voluntary admission: employee missed ABPI exam first-year deadline (Clause 9.4)

GrΓΌnenthal admitted a market access employee calling on HCPs did not take the ABPI exam modules within the first year of employment.…

2023
CASE
AUTH/3813/8/23 AstraZeneca

AstraZeneca: employees’ LinkedIn β€˜likes’ treated as advertising a POM to the public (Tagrisso) (AUTH/3813/8/23)

Three UK AstraZeneca employees β€˜liked’ a third‑party LinkedIn post about pre-clinical osimertinib resistance reversal. PMCPA said the likes disseminated favourable content to…

2023
CASE
AUTH/3819/9/23 GlaxoSmithKline ⭐ Case of the Week

GSK: Responsive disease-awareness website breached Clause 8.3 due to uncertified desktop vs mobile final forms (AUTH/3819/9/23)

PMCPA found GSK’s Tackle Meningitis site showed substantive desktop vs mobile differences on two pages. Each final form should have been certified…

2023
CASE
AUTH/3830/9/23 Daiichi-Sankyo UK

AUTH/3830/9/23: Complainant v Daiichi Sankyo UK β€” event sponsorship declaration (No breach)

Complaint alleged Daiichi Sankyo’s sponsorship of an event wasn’t clear on the website home/registration pages. Panel found sponsorship disclosure and sponsor list…

2023
CASE
AUTH/3857/11/23 AstraZeneca

AstraZeneca breached Clause 12 requirements in LinkedIn post promoting Calquence National Summit (AUTH/3857/11/23)

PMCPA ruled an AstraZeneca LinkedIn post was promotional for Calquence (CLL) and lacked mandatory digital prescribing/safety information (PI, INN, AE statement, black…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training